Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PDCD1) · developed by Innovent Biologics Co.
Phase 3Most advanced trial
3Registered trials
What is Sintilimab?
Sintilimab is a recombinant human monoclonal antibody that binds the PD-1 receptor on T cells and blocks its interaction with the ligands PD-L1 and PD-L2, restoring T-cell activation and anti-tumor immune responses. It is being studied in advanced endometrial cancer, advanced solid tumors and advanced renal cell carcinoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
IBI-308
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PDCD1), Programmed cell death 1 ligand 1 (CD274) (binding partner it blocks), Programmed cell death 1 ligand 2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Inhibitor of Programmed cell death protein 1 (PDCD1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.